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NF-KB is an important transcription factor regulating expression of genes involved in immune function,
inflammation, and cellular growth control. NF-KB activity is induced by numerous stimuli, such as phorbol
esters, B- and T-cell mitogens, the cytokines tumor necrosis factor and interleukin-1, and serum growth
factors. The standard model for the induction of NF-KB activity involves the release of the transcription factor
from a cytoplasmic inhibitor termed IKB, allowing translocation ofNF-KB to the nucleus. IKB contains multiple
copies of the so-called ankyrin repeat, which are apparently necessary for its function. Subunits comprising
NF-,cB and related binding activities are members of the Rel multigene family. Two such subunits, p50 and p52
(also called p5OB), are proteolytically processed from precursors of 105 kDa (also called p105 and NFKB1) and
100 kDa (also called plOO, NFKB2, and Lyt-10), respectively. Both contain N-terminal Rel-homologous
domains as well as multiple copies of C-terminal ankyrin repeats. We show here that NF-KcB plOO is a
component ofthe previously identified DNA-binding activity H2TF1. In addition, we show that plOO is localized
in the cytoplasm in HeLa cells, where it is associated with c-Rel, p50, or p65 (ReIA). In transient-transfection
assays, plOO represses the ability of NF-KB p65 to activate a KB-containing reporter construct. Transfection of
plOO also results in a loss of nuclear p65 DNA binding to a KB probe, as measured by an electrophoretic
mobility shift assay, and a loss of nuclear p65 immunoreactivity, as measured by immunoblotting. This loss of
nuclear p65 is paralleled by a gain of p65 DNA-binding activity and immunoreactivity in the cytoplasm. We
interpret these data as demonstrating that plOO functions as an IKB-like molecule to sequester Rel family
members in the cytoplasm. Proteolytic processing of plOO to the activator p52 is predicted to generate several
new forms of Rel family heterodimers and therefore represents a form of regulation of NF-KB activity distinct
from the classic IKB pathway.
The transcription factor NF-KB, first described as a regu-
lator of the immunoglobulin kappa (Ig K) light-chain gene (38,
58), is now understood to play an important role as an
activator of numerous genes of the immune and inflamma-
tion systems as well as of human immunodeficiency virus
(HIV) gene transcription (4, 24, 38, 45). NF-KB activity,
while constitutive in mature B cells, is rapidly induced by
stimuli such as exposure to cytokines, mitogens, phorbol
esters, reactive oxygen intermediates, and viral infection (4,
5, 38, 39, 57, 59). One mechanism by which this rapid
induction of NF-KB activity is made possible is the storage of
presynthesized NF-KB in the cytoplasm, bound to the inhib-
itor IKB (1, 2). While the mechanism by which NF-KB is
liberated from its inhibitor is not well understood, in vitro
data suggest that the phosphorylation of IKB markedly
reduces its affinity for NF-KB subunits (22, 60). In addition,
recent work has shown that multiple inducers of NF-KB lead
to the phosphorylation of IKBa (8) and to the rapid loss of
this inhibitor protein (8, 14, 63). Release from IKB unmasks
the nuclear localization signal for NF-KB, allowing it to
translocate to the nucleus, where it may then bind to a family
of related DNA-binding sites (9).
The best studied form of NF-KB consists of a heterodimer
of a 50-kDa (p5O) and a 65-kDa (p65 [RelA]) subunit (3, 33).
The cloning of the cDNAs encoding these subunits has
shown that they are both homologous with the c-rel proto-
oncogene and with the Drosophila maternal-effect gene
dorsal (12, 23, 35, 50, 54). In addition, the cloning of p50
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revealed that it is derived from the N terminus of a 105-kDa
precursor (p105 [NFKB1]) via an ATP-dependent proteo-
lytic pathway (20). Deletion studies have shown that DNA
binding is detectable only after removal of the C-terminal
portion of p105 (23, 35). This C-terminal region of p105
contains an interesting repeat structure of conserved ele-
ments found both in erythrocyte ankyrin and in several cell
cycle control proteins (23, 35). p5O, p65, and c-Rel contain
an N-terminal Rel-homologous region which contributes
dimerization, nuclear localization, and DNA-binding do-
mains to these proteins (9, 24, 28, 50). Homodimers of p5O
and of p65 as well as heterodimers of c-Rel with either p5O or
p65 can bind KB sites (25, 35, 50, 54, 64). Characterization of
these dimers has revealed that each has its own subset of
preferred DNA-binding sites within the KB consensus se-
quence (25, 37). In addition, recent studies have shown the
association of the p105 precursor with c-Rel, p5O, and p65
(16, 44, 46, 53). This suggests that NF-KB subunits may be
part of a complex regulatory network in which different
subsets of genes might be activated by different dimeric
combinations of Rel and NF-KB subunits.
The retention of NF-KB and Rel proteins in the cytoplasm
is mediated by a family of related proteins referred to
collectively as IKB. Multiple forms of IKB have been cloned,
including IKBa/MAD-3, its chicken homolog pp4O, Bcl-3,
and IKB-y (26, 27, 30, 34). Strikingly, each form of IKB
contains multiple copies of ankyrin repeats highly similar to
those of p105 (19, 26). Deletion studies have shown that
these ankyrin repeats play a crucial role in the inhibition of
DNA binding (31).
The high degree of conservation of the rel homology
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domain led a number of laboratories to search for other
rel-related genes. A cDNA similar to that encoding p105 was
thus identified and named plOO (also referred to as p98 and
NFKB2) (43, 56). Interestingly, the gene encoding this
protein was also identified by the sequencing of the (10;
14)(q24;q32) translocation breakpoint associated with cer-
tain B-cell leukemias and named lyt-10 (47). Additionally,
plOO (Lyt-10) was identified in a library of mitogen-induced
genes (10). Sequence comparisons of rel family members
show that plOO is most closely related to p105. Both proteins
contain an N-terminal Rel homology domain, nuclear local-
ization sequences, and C-terminal ankyrin repeats (43, 47,
56). Like p105, plOO is a precursor protein which is pro-
cessed to a 52- to 55-kDa protein (p52) (43). N-terminal
truncations of plOO have been shown to bind to p5O, p65, and
c-Rel and, when heterodimerized with p65, to activate gene
transcription in transient-transfection assays (43, 52, 56).
The potentially oncogenic form of plOO (Lyt-10) is fused to
the immunoglobulin Ca gene, resulting in a chimera which
retains the Rel homology domain but has lost the C-terminal
ankyrin repeats. Unlike plOO, this chimera readily binds to
the KB DNA motif in vitro (47). While the potential mecha-
nism of oncogenesis through plOO is unknown, these data
suggest that the C-terminal ankyrin repeats may play an
important role in any growth-regulatory functions of this
protein.
H2TF1 was identified in HeLa whole-cell extracts by its
interaction with the region I enhancer of the murine H-2K'
gene (6). This mode of identification suggested that H2TF1
plays a role in the regulation of major histocompatibility
complex (MHC) gene expression. Initially, H2TF1 was
identified in electrophoretic mobility shift assays (EMSAs)
with a large fragment of the H-2K" promoter. This binding
site was then localized to the region I enhancer by methyl-
ation interference (6). Both NF-KB and H2TF1 bind to this
site, exhibiting a slightly different methylation interference
pattern (7). The similarity in binding sites led to the concept
that H2TF1 was possibly KBF1, recently identified as the
NF-KB p5O homodimer. In this report, we identify a DNA-
binding component of H2TF1 as the Rel family member
plOO. In addition, we show that plOO is localized to the
cytoplasm and heterodimerizes with p5O, p65, and c-Rel.
Cytoplasmic plOO can repress gene activation mediated by
p65 through its ability to sequester p65 in the cytoplasm.
These properties suggest that plOO can function as an IKB.
As plOO is proteolytically cleaved to give rise to p52, this
predicts the formation of several new heterodimeric forms of
Rel/NF-KB subunits and suggests that proteolytic cleavage
of NF-KB precursor molecules represents a mechanism of
regulating NF-KB activity distinct from the classic IKB
pathway.
MATERIALS AND METHODS
Cell culture. HeLa cells were grown in spinner cultures in
Eagle's minimal essential medium (suspension) with 2 mM
glutamine, 5% fetal calf serum, 5% horse serum, 100 U of
penicillin per ml, and 100 ,g of streptomycin per ml. Cell
densities were kept between 2 x 105 and 1 x 106/ml during
culture, and cells were harvested at a density of 5 x 105 to 1
x 106/ml for the preparation of extracts.
COS cells were maintained in Iscove's Dulbecco's modi-
fied Eagle's medium with 5 mM glutamine, 7.5% fetal calf
serum, 100 U of penicillin per ml, and 100 ,g of streptomycin
per ml and passaged every 3 to 4 days. After passage 15, the
cells were discarded.
TABLE 1. KB sites used in this study
Enhancer Sequence Strand
MHC RI TGGGGATTCCCCA +
P2-Microglobulin AGGGACTTTCCCA -
MHC RIla CTGGGCTTCCCCA -
Ig K AGGGGACTTTCCG +
HIV long terminal repeat TGGGGACTTTCCA +
c-myc CGGGTTTTCCCCA +
MHC mutant TGCGGATTCCCGA +
Extract preparation. HeLa whole-cell extracts were pre-
pared and partially purified by passage over a phosphocel-
lulose column (6). The 0.35 M salt fraction was collected and
is referred to as HeLa B. For studies comparing cytoplasmic
and nuclear proteins, cells were washed in phosphate-
buffered saline (PBS) and lysed in E buffer (0.3% Nonidet
P-40 [NP4O], 10 mM Tris [pH 8.0], 60 mM NaCl, 1 mM
EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl
fluoride) by 5 min of incubation on ice. Nuclei were pelleted
by spinning for 5 min at 2,500 rpm at 4°C in an Eppendorf
microcentrifuge, and the supernatant was saved as the
cytoplasmic extract. Glycerol was added to cytoplasmic
extracts to a final concentration of 20%, after which the
extracts were stored at -80°C until use. Nuclei were washed
in buffer E without NP-40 and resuspended in 100 ,ul of
buffer C (20 mM HEPES [N-2-hydroxyethylpiperazine-N'-
2-ethanesulfonic acid, pH 7.9], 0.75 mM spermidine, 0.15
mM spermine, 0.2mM EDTA, 2 mM EGTA [ethylene glycol
tetraacetic acid], 2 mM dithiothreitol, 20% glycerol, 1 mM
phenylmethylsulfonyl fluoride). When mentioned, the nuclei
were layered over a 0.5-ml sucrose pad and spun for 10 min
at 2,500 rpm at 4°C in a desktop refrigerated centrifuge, and
the pellet was resuspended in buffer C. NaCl was added to a
concentration of 0.4 M, and the nuclei were gently shaken
for 20 min at 4°C. The nuclei were then pelleted by spinning
for 10 min at top speed at 4°C in an Eppendorf microcentri-
fuge, and the nuclear extract supernatant was stored at
-80°C until use.
DNA-binding reactions and EMSAs. DNA sequences used
as probes in EMSAs are shown in Table 1. These DNAs are
derived from oligonucleotides cloned into the BamHI site of
a pUC polylinker and liberated by EcoRI and HindIII
digestion. The DNA fragment containing the binding site
was then purified on 1% low-melting-point agarose gels and
labeled by a fill-in reaction with the Klenow fragment of
DNA polymerase I and [a-32P]dATP as described before (6).
Additionally, some mobility shift assays were performed
with a DNA probe designed for UV cross-linking studies.
The synthesis of this probe is described below.
Binding reactions were performed by first incubating 5 to
10 ,ug of cell extract with 0.5 to 2 ,ug of poly(dI-dC) in binding
buffer (10 mM Tris [pH 7.7], 50 mM NaCl, 20% glycerol, 1
mM dithiothreitol, 0.5 mM EDTA) for 10 min at room
temperature. Approximately 10,000 cpm (0.2 ng) of probe
was then added and allowed to bind for approximately 30
min. The reaction mix was then loaded onto native 5%
acrylamide gels, prepared with either TAE (6.7 mM Tris, 3.3
mM sodium acetate, 1 mM EDTA, pH adjusted to 7.9) or
0.25x TBE (22.3 mM Tris, 22.3 mM borate, 0.5 mM EDTA).
We have found that TAE gels are necessary to visualize
non-cross-linked H2TF1 by EMSA. Supershift experiments
were performed by incubating binding reaction mixes with 1
pl of antiserum for 15 min at room temperature. Gels were
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analyzed either by autoradiography or with a PhosphorIm-
ager (Molecular Dynamics).
UV cross-linking. Two template oligonucleotides were
synthesized, UV1 (CAGGGCTGGGGATTCCCCATCTCC
ACAGTTTCACTI'C) and UV3 (CAGGGCTGCGGAYT
CCCGATCTCCACAGYTTCACTTC), along with primer
UV2 (GAAGTGAAACTGTGG). UV1 corresponds to bases
-178 to -141 of the region I enhancer of the H-2Kb gene,
which contains a strong KB motif (7). UV2 and UV1 were
annealed to form UV21 and extended with Klenow fragment
in the presence of bromodeoxyuridine and [a-32P]dCTP as
described before (17). UV2 and UV3 were annealed and
extended as above to make UV23, a mutant probe analogous
to the MHC mutant probe (Table 1). Approximately 50 pg of
cell extract was incubated for 10 min with 2 ,ug of poly(dI-
dC) in binding buffer, and 2 x 105 to 1.5 x 106 cpm of probe
was added to a final volume of 40 ,ul in a 1.5-ml microcen-
trifuge tube. The reaction was allowed to bind for 30 min at
room temperature. It was then placed in a rack in the cold
room so that a 302-nm UV light box could be placed directly
on top of the open microcentrifuge tube. In this fashion, the
binding reaction mix was irradiated with UV light for times
ranging from 15 to 90 min. Cross-linked material was then
analyzed either by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) or by mobility shift assay.
Partial proteolysis. Incomplete proteolysis of H2TF1 was
achieved with the endoproteinase Glu-C (V8 protease).
UV-irradiated binding reaction mixes were run on a native
acrylamide gel (EMSA) to separate specific DNA-protein
complexes. These complexes were located within the wet gel
by autoradiography, and the bands were excised with a razor
blade. The gel slices were then equilibrated with SDS
loading buffer by boiling for 5 min and loaded onto a 10%
acrylamide-SDS gel with a 5% acrylamide stacking gel.
These samples were then overlaid with 25 ,ul of V8 protease
(O to 250 ng) in dilution buffer (250 mM Tris [pH 6.8], 0.1%
SDS, 1 mM EDTA, 10% glycerol, 40 mM 2-mercaptoetha-
nol, 0.005% bromophenol blue). When all proteins were
focused in the stacking gel, the power was shut off for 10 to
30 min to allow the V8 to partially digest the proteins
present, as described before (18, 21). The power was then
restored, the gel was run to completion and dried, and
DNA-cross-linked proteins were visualized by autoradiogra-
phy.
Antibodies and immunoprecipitations. Ab2, a gift of A.
Israel, is a polyclonal antiserum raised against the p5O
subunit as described before (35). This antiserum recognizes
p5O homodimers (KBF1) and p5O-p65 heterodimers (NF-
KB). Ab22, a gift of M. Karin, is a polyclonal antipeptide
antiserum raised against a peptide encoding amino acids 1 to
14 of plO5/pSO and has a higher avidity for p50 homodimers
than p5O heterodimers (43). Ab9 is a polyclonal antiserum
raised against a peptide encoding amino acids 6 to 20 of
IKBa/NAD-3. Ab9 recognizes IKB but not p5O or p65 in
immunoprecipitation assays (9). Ab265, a gift of N. Rice, is
a polyclonal antipeptide antiserum specific for human c-Rel,
prepared as described before (15). AbllOl is a polyclonal
antiserum raised against a peptide encoding amino acids 1 to
21 of p65. Ab2932, a gift of M. Karin, is a polyclonal
antipeptide antiserum raised against a peptide (peptide 2932)
encoding amino acids 1 to 19 of plOO (Lyt-10) and has a
higher avidity for plOO homodimers than for plOO het-
erodimers (43).
Immunoprecipitations of cross-linked proteins were per-
formed by combining a 40-pul cross-linked binding reaction
mix (containing 5 x 105 cpm of freshly synthesized UV21
probe and S ,ul of HeLa cell extract) with 400 RI of RIP buffer
(25 mM Tris [pH 7.6], 150 mM NaCI, 2 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 0.5% NP-40) and 1 to 2 ,ul of
antiserum. For some immunoprecipitations, 4.4 ,ul of 10%
SDS was added to cross-linked binding reaction mixes and
the samples were boiled for 5 min to abolish protein-protein
interactions. Antiserum and 400 ,1u of RIP buffer were then
added. Reaction mixes were rotated for 30 min at 4°C. The
samples were then transferred to tubes containing a 1:1
slurry of protein A-Sepharose (PAS) in PBS plus 1% bovine
serum albumin and rotated for 60 min at 4°C. The PAS was
then washed twice in each of the following buffers as
described before (62): (i) 1 M NaCl, 20 mM Tris (pH 7.6),
plus 0.1% NP-40; (ii) 0.2 M NaCl, 20 mM Tris (pH 7.6), and
1% NP-40; (iii) 20 mM Tris (pH 7.6) plus 0.1% NP-40; and
(iv) 50 mM Tris (pH 6.8). The pellet was then resuspended in
100 ,u of SDS-PAGE loading buffer, boiled for 5 min loaded,
and run on 7% acrylamide-SDS gels.
35S-labeled HeLa cell extracts were immunoprecipitated
by combining 2 to 5 RI of antibody with 100 to 200 ,ul of
extract and processed as above. For PAS elution experi-
ments, 35S-labeled HeLa cell extracts were immunoprecipi-
tated, and PAS pellets, washed as described above, were
incubated overnight in 200 ,ul of RIP buffer containing 50 ,ug
of peptide 2932 per ml as described before (36). The super-
natant was then collected and reimmunoprecipitated with a
different antibody, and new PAS was added and washed as
above. The pellets were resuspended in 100 RI of SDS-
PAGE loading buffer plus 10 ,g of bovine serum albumin as
a carrier, boiled for 5 min, and analyzed by SDS-PAGE.
3"S labeling of HeLa cells. HeLa cells were grown to a
density of 107 cells per 35-mm-diameter plate in Dulbecco's
modified Eagle's medium without methionine for 1 h, after
which [35S]methionine (Translabel; ICN) was added to 500
,uCi/ml. Cells were incubated for 2 h, harvested, placed on
ice, and washed with PBS. The cells were then lysed with 1
ml of RIP buffer on ice for 5 min and spun at 14,000 rpm for
10 min at 4°C. Immunoprecipitations were typically per-
formed on 100 to 200 RI of extract. Nuclear and cytoplasmic
extracts were prepared as described above except that after
cell lysis, washed nuclei were boiled for 5 min in 44 pl of E
buffer plus 1% SDS; 400 ,ul of RIP buffer was then added,
and immunoprecipitations were performed as described
above.
Transfections, CAT assays, and protein assays. HeLa cells
were transfected by electroporation with the Bio-Rad Gene
Pulser with a capacitance extender. Approximately 3 x 106
to 1 x 107 cells were transfected in a volume of 0.5 ml at a
setting of 300 V and 960 ,uF in a 0.4-cm gapped cuvette.
Transfected samples were transferred to 25-cm flasks in 10
ml of medium and incubated at 37°C for 16 to 24 h. COS cells
were transfected by the DEAE-dextran method (32). Cells
were harvested after 48 h, and chloramphenicol acetyltrans-
ferase (CAT) activity was determined as described before
(48). The data were normalized to input protein levels,
assayed by the method of Bradford (13) with Bio-Rad dye
reagent according to the manufacturer's instructions.
Immunoblots. Extracts were run through SDS-10% PAGE
gels and electroblotted to nitrocellulose filters in 0.025 M
Tris base-0.2 M glycine-20% methanol at 100 V for 1 h at
4°C. The nitrocellulose was blocked for 30 min in 1% bovine
serum albumin in TBST (10 mM Tris, 150 mM NaCl, or
0.05% Tween 20). Antiserum 1101, specific for p65, was
diluted 1:2,000 in TBST. Blots were shaken for 30 min in
diluted antiserum and washed three times in TBST. Fluores-
cein isothiocyanate-conjugated anti-rabbit immunoglobulin
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FIG. 1. Binding specificity of H2TF1. A phosphocellulose frac-
tion of a HeLa whole-cell extract was incubated with the labeled
DNA fragments listed in Table 1. The binding reaction mixes were
then analyzed on a TAE-5% acrylamide native gel, which was
subsequently dried and visualized by autoradiography. Complexes
Cla, Clb, and C2 are indicated by the arrows. The labeled DNA
fragment present in the binding reaction mix is indicated over each
lane.
G (Promega) was diluted 1:7,500. Blots were incubated for
30 min in diluted secondary antibody and washed three times
in TBST. Immunoreactivity was visualized by alkaline phos-
phatase color reaction with the ProBlot kit (Promega) ac-
cording to the manufacturer's instructions.
RESULTS
Binding specificity of H2TF1. H2TF1 was originally iden-
tified by its ability to bind to a site in the region I enhancer
of the H-2Kb MHC class I gene (6). NF-KB binds to this
same region with high affinity, competes with H2TF1 for
binding in vitro, and generates a methylation interference
pattern closely related to that of H2TFl (7). In order to
better understand the sequence requirements for the binding
of these two factors, we prepared a panel of NF-KB binding
sites and tested them for binding to H2TF1. The HeLa B
phosphocellulose fraction (6) of a HeLa whole-cell extract
(from which H2TF1 was originally identified) was used as a
source of H2TFl for this experiment, and binding was
assayed by mobility shift. The sequences used as DNA
probes for this study are listed in Table 1.
The MHC region I enhancer binding site (MHC RI) was
shifted as at least three complexes by proteins within the
HeLa B fraction (Fig. 1, lane 1). The upper doublet will be
referred to in this report as complexes la and lb, while the
lower band will be referred to as complex 2. Complex 2,
corresponding to H2TF1 as originally identified (6), forms
most readily with DNA sequences derived from the MHC
class I and 02-microglobulin promoters (Fig. 1). In addition,
small amounts of complex 2 form with a DNA encoding an
NF-KB site located approximately 1,100 bp upstream from
the murine c-myc transcription start site (Fig. 1). The com-
plex 1 doublet forms most readily with the MHC region I
enhancer and 32-microglobulin-derived sequences; how-
ever, it forms with other NF-KB sites, including those found
in the Ig K and c-myc enhancers and in the HIV long terminal
repeat (Fig. 1). An imperfect repeat of the MHC RI sequence
(MHC RIIa) is found 4 bases upstream of MHC RI, stretch-
ing from -177 to -189 (Table 1). This site forms only
complex lb when tested against the HeLa B extract (Fig. 1).
A mutant of the MHC RI site with a double point mutation is
incapable of forming DNA-protein complexes, illustrating
the specificity of interactions with other members of the
panel (Fig. 1). Thus, H2TF1 complex 2 binds to a subset of
NF-K.B sites, while complexes la and lb are formed in the
presence of virtually all NF-KB sites tested.
Identification of a DNA-binding subunit of H2TF1 by DNA
cross-linking. We then designed a probe (UV21) correspond-
ing to the H-2Kb region I enhancer and used a UV cross-
linking protocol to determine the size(s) of the DNA-binding
component(s) of H2TF1 (17). When used in a mobility shift
assay with the HeLa B fraction, the UV21 probe generated
a pattern of DNA-protein complexes similar to that shown in
Fig. 1, lane 1 (data not shown). HeLa B-UV21 binding
reactions were UV cross-linked for increasing lengths of
time and analyzed by SDS-PAGE. Under these conditions, a
major cross-linked protein doublet was observed with a
mobility corresponding to approximately 125 kDa (Fig. 2A,
lanes 1 to 4). The efficiency of the cross-linking reaction was
seen to be directly proportional to the length of time that the
reaction mix was UV irradiated. Proteinase K treatment
destroys the cross-linked complex, establishing the DNA-
binding component as a protein (Fig. 2A, lane 5). When UV
irradiation was omitted, no complex was formed (data not
shown).
The specificity of this interaction was explored by adding
DNA competitors during the binding reaction. Competition
with a 10-fold excess of unlabeled UV21 DNA markedly
decreased binding, while a 10-fold excess of a DNA contain-
ing a mutated H2TF1 binding site (UV23) had little effect on
the lower member of the doublet (Fig. 2A, lanes 6 and 7). In
addition, no protein-DNA complexes in the 125-kDa range
were detected when labeled UV23 was used in a binding
reaction (Fig. 2A, lane 8). As will be shown below, cross-
linked NF-KB subunits form much smaller complexes. Thus,
while H2TF1 shares binding sites with NF-K-B, it contains a
DNA-binding subunit of a size quite different from that
described for NF-KB and c-Rel.
Subceliular localization of H2TF1. Given the similarities in
DNA-binding specificity between NF-KB and H2TF1 and the
cytoplasmic localization of inactive NF-KB, we were inter-
ested in determining the subcellular localization of H2TF1.
We prepared nuclear and cytoplasmic extracts as described
in Materials and Methods, taking care to avoid cytoplasmic
contamination by spinning nuclei over a sucrose pad. Under
these conditions, virtually all the H2TF1 DNA-binding ac-
tivity was found in cytoplasmic extracts, with only trace
amounts of DNA-binding activity in nuclear extracts (Fig.
2B, lanes 1 and 2). Interestingly, deoxycholate dissociation
was not required to observe cytoplasmic H2TF1 DNA-
binding activity (6). Figure 2B (lanes 1 and 2) identifies three
cytoplasmic complexes as Cl through C3 and two nuclear
complexes as Ni and N2. In order to determine the size of
the DNA-binding components of these complexes, solution
cross-linked material was separated by EMSA, excised from
the native gel shown in Fig. 2 (lanes 1 and 2), equilibrated
with SDS-PAGE loading buffer, and placed into the wells of
an SDS-PAGE gel. As shown in Fig. 2B, complexes Cl and
C2 (lanes 3 and 4) both contain a protein which, upon
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UV21 u probe cross-linking to UV21, migrates at 125 kDa. These major
cross-linked complexes derived from the EMSA complexes
- UV21 UV23 - competitor Cl and C2 migrate identically in SDS-PAGE gels to the
+ - - - proteinase K solution cross-linked 125-kDa complex of Fig. 2A (data notshown). In comparison, with Phosphorlmager cassette ex-
posure times of up to 4 days, we failed to detect this complex
in lanes corresponding to C3, Ni, or N2. In addition to the
major 125-kDa complex observed in Cl and C2, we observed
various amounts of faster-migrating complexes, similar to
those in Fig. 2A (compare lane 4 in Fig. 2Awith lane 4 in Fig.
2B).
The identical mobilities of the cross-linked Cl and C2
complexes suggested that these complexes contained the
same DNA-binding subunit. In order to further compare the
Cl- and C2-derived cross-linked protein complexes, we
subjected these complexes to limited proteolytic digestion
with endoproteinase Glu-C (V8) during SDS-PAGE. Cyto-
plasmic extracts were cross-linked to the UV21 probe and
separated by mobility shift assay, and the shifted complexes
corresponding to Cl and C2 were excised after autoradiog-
5 6 7 8 raphy as above. These gel slices were then equilibrated with
SDS buffer, loaded into SDS-PAGE wells, overlaid with
SDS-PAGE protease solution, and electrophoresed as described in Ma-
C1 C2 C3 NI N2 terials and Methods. As shown in Fig. 2C, both complexes,upon partial digestion by V8, generated a similar pattern,
suggesting that these proteins are highly similar or identical.
Interaction of the DNA-binding subunit of H2TF1 with
;¢''.,;.^e. ,,'.'.''z,'.!'z,.~ .s .antiserum specific for NF-cB/Rel family members. The strong
similarity between the H2TF1 and NF-KB methylation inter-
ference patterns and the cytoplasmic localization of both
molecules suggested that H2TF1 might have some structural
similarities to NF-KB/Rel family members (7). We explored
this possibility with a panel of NF-KB and Rel antibodies (see
Materials and Methods). When antiserum raised against p5O,
3 4 5 6 7 p65, or c-Rel was incubated with binding reaction mixes
containing the HeLa B fraction and analyzed by mobility
o00 ng 250 ng shift assay, no changes in mobility were observed (Fig. 3,
V8 V8 lanes 1 to 5). In comparison, when antiserum raised against
C1 C2 C1 C2 plOO (Lyt-10) was added to binding reaction mixes, the C2
complex was shifted to the top of the gel (Fig. 3, lane 6). This
interaction is specific in that the peptide against which the
plOO antibody was made (plOO peptide) blocked the super-
shift, while an irrelevant peptide had no effect (Fig. 3, lanes
7 and 8).
As it was difficult to determine whether the plOO antiserum
supershifted Cl in the presence of supershifted C2, we
repeated the supershift experiment with the Ig K probe,
which shifts only the Cl complexes. While antiserum raised
against p5O, p65, or c-Rel had little effect (data not shown),
FIG. 2. Covalent cross-linking of DNA-binding subunits of
H2TF1 to a DNA probe. (A) The UV21 probe was incubated with a
HeLa whole-cell extract and exposed to 302-nm UV irradiation.
Lanes 1 to 4 correspond to 15, 30, 60, and 90 min of UV irradiation,
respectively. The samples were then subjected to SDS-PAGE and
visualized by autoradiography. Samples shown in lanes 5 to 8 were
UV irradiated for 90 min and analyzed by SDS-PAGE. In lane 5, the
binding reaction mixwas incubated with proteinase K for 30 min after
cross-linking. In lane 6, the UV21 probe was incubated with extract
in the presence of a 10-fold excess of unlabeled competitor UV21
DNA prior to cross-linking. In lane 7, the UV21 probe was incubated
with extract in the presence of a 10-fold excess of unlabeled compet-
itor UV23 mutant DNA prior to cross-linking. In lane 8, extract was
cross-linked to the UV23 mutant DNA probe. (B) Binding reaction
mixes were UV irradiated for 90 min and then subjected to native gel
electrophoresis (EMSA). Gel slices containing shifted DNA-protein
complexes were excised after autoradiography, equilibrated with
SDS loading buffer, and analyzed by SDS-PAGE. Lanes 1 and 2,
EMSA of nuclear and cytoplasmic binding reactions, respectively.
Shifted complexes are identified as Cl through C3 (lane 1) and Ni
and N2 (lane 2). The band at the bottom of lanes 1 and 2 represents
free probe. Lanes 3 to 7, excised gel slices containing the bands
identified in lanes 1 and 2 which were analyzed by SDS-PAGE. The
excised complex is shown at the top of each lane. (C) Partial
proteolysis of the Cl and C2 complexes shown in panel B. Binding
reaction mixes containing HeLa cytoplasmic extract were cross-
linked in triplicate and separated by mobility shift gel electrophore-
sis. The appropriate bands were excised, equilibrated with SDS
loading buffer, loaded onto a 10% SDS gel, and overlaid with 0, 100,
or 250 ng of endoproteinase C (V8) as shown above the lanes. The
samples were digested as described in Materials and Methods.
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FIG. 3. Interaction of H2TF1 with NF-KB/Rel antiserum in a
mobility shift assay. Binding reaction mixes prepared with HeLa
cytoplasmic extracts and either the UV21 probe (lanes 1 to 8) or the
Ig K probe (lanes 9 to 13) were allowed to equilibrate for 30 min, after
which 1 Al of either preimmune serum or NF-KB/Rel antiserum was
added. Where indicated, peptide was added to the binding reaction
mixes just before antibody addition. Binding reaction mixes were
analyzed by EMSA in TAE gels. The antiserum and/or peptide
added to each reaction mix is shown above each lane. The band at
the bottom of the gel represents free probe.
plOO antiserum clearly supershifted the lower Cl complexes
(Fig. 3, lane 11). The addition of preimmune serum markedly
increased nonspecific DNA binding in the upper region of
the Cl complexes, hindering the interpretation of this exper-
iment (Fig. 3, compare lanes 9 and 10). This interaction
between plOO antiserum and the Cl complexes could be
blocked by plOO peptide but not by an irrelevant peptide
(Fig. 3, lanes 12 and 13). Thus, anti-plOO antiserum interacts
with some of the Cl EMSA complexes as well as with the C2
complex.
HeLa cell plOO migrates as a 114-kDa protein when
analyzed by SDS-PAGE (43). The ability of anti-plOO anti-
serum to interact with both Cl and C2 and the similarity in
size between plOO and the 125-kDa complex strongly suggest
that plOO is a component of H2TF1. It is important to note
that the lack of interaction between other NF-KB or Rel
antibodies and these complexes does not indicate their
absence, only our inability to demonstrate their presence in
this assay. Indeed, as described below, Rel/NF-KB family
members do interact with cytoplasmic plOO.
Physical association of plOO (Lyt-10) with Rel/NF-KB sub-
units. To further explore the associative properties of the
major DNA-binding component of H2TF1, we covalently
labeled KB motif-binding proteins from HeLa extracts by
UV cross-linking with the UV21 DNA probe. HeLa cell
cytoplasmic extracts, when cross-linked to the UV21 probe
and analyzed directly by SDS-PAGE, generate one major
DNA protein complex at 125 kDa and several other com-
plexes of 88, 80, 65, and 60 kDa (Fig. 4A, lane 1). As will be
shown below, these complexes consist of plOO, c-Rel, p65,
p52 (a product derived from plOO), and p5O, respectively. It
is useful to consider Fig. 4B when analyzing the data shown
in Fig. 4A. The UV21 probe contains a palindromic KB site
which is expected to bind dimeric proteins. By design, there







FIG. 4. Immunoprecipitation of cross-linked DNA-protein com-
plexes. (A) Binding reaction mixes were prepared with HeLa
cytoplasmic extracts and the UV21 probe and UV irradiated for 90
min, and cross-linked complexes were immunoprecipitated as de-
scribed in the text. Immunoprecipitated complexes were then ana-
lyzed by SDS-PAGE. The antiserum used for each immunoprecip-
itation is shown above each lane. Molecular size markers are shown
to the left of lane 1 (in kilodaltons). The samples shown in lanes 10
to 14 are labeled boiled extract to indicate that protein-protein
interactions were disrupted as described in Materials and Methods.
Lane 1, 1/10 of a standard 40-,ul cross-linking reaction mix of
cytoplasmic extract (CE) was loaded directly onto the gel. Lanes 2
to 8, antiserum additions are as shown above each lane. Lane 9, a
sample was processed without antiserum addition. Lanes 10 to 14,
cross-linking reaction mixes were processed to disrupt protein-
protein interactions and immunoprecipitated with the antiserum
shown above each lane. Cross-linked proteins were visualized by
autoradiography. (B) Model of the experiment shown in panel A,
lane 3. Ovals represent the NF-KB p5O subunit and plOO (Lyt-10).
Shaded rectangles represent the UV21 DNA probe, with the posi-
tion of the bromodeoxyuridine substitution shown as a U within the
sequence. Solid triangles connecting the U to one of the ovals
represent covalent cross-linking of the protein to the DNA. The
inverted Y represents antibodies from the Ab2 antiserum and is
labeled Ab2. The binding site is palindromic; hence, a dimer can
bind in either orientation. This is shown by the lower and upper
groups. The expected complex generated from each group is shown
to the right of the arrows.
ing site; hence, only one member of the dimer can be
covalently linked to the probe. As shown by way of example
in Fig. 4B, the cross-linking of the probe to the plOO subunit
of a putative p100-p50 heterodimer results in a 125-kDa
complex when analyzed by SDS-PAGE. Cross-linking of the
probe to the p5O subunit, however, results in a 60-kDa
cross-linked complex. Consistent with this model, both
cross-linked species can be immunoprecipitated by an anti-
p5O antibody, as shown in Fig. 4A, lane 3.
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When cross-linked extract is incubated with anti-plOO
antiserum, all of the above complexes are coimmunoprecip-
itated, but the precipitate is enriched in the 125-kDa (plOO)
and 65-kDa (p52) species (Fig. 4A, lane 2). When one of
several antisera raised against p5O is substituted, the 60-kDa
(p5O) species is precipitated predominantly, along with the
125-kDa (plOO) species (Fig. 4A, lanes 3 and 4). In addition,
a polyclonal antiserum raised against p5O (Ab2), which
recognizes both homodimeric and heterodimeric p5O, immu-
noprecipitates a trace of the 80-kDa (p65) species (Fig. 4A,
lane 3), while an antipeptide antiserum (Ab22) characterized
as binding preferentially to p50 homodimers does not immu-
noprecipitate this species (Fig. 4A, lane 4). An antibody
specific for IKBaIMAD-3 does not coimmunoprecipitate any
of the DNA-bound complexes (Fig. 4A, lane 5). An antipep-
tide antiserum raised against p65 immunoprecipitates pri-
marily the 80-kDa (p65) species but also brings down plOO,
p52, and a trace of p5O (Fig. 4A, lane 6). Finally, an
antipeptide antiserum raised against c-Rel primarily immu-
noprecipitates the 88-kDa (c-Rel) species but also brings
down plOO and a trace of p52, p5O, and p65 (Fig. 4A, lane 7).
In lanes 3, 6, and 7 of Fig. 4A, small amounts of cross-linked
p5O, p52, and p65, respectively, were detected. Under these
UV cross-linking conditions, we may be cross-linking a
small amount of IKB-associated proteins. Alternatively,
these might represent a small population of multimeric
complexes. These possibilities are explored more fully in the
Discussion.
The above interpretive description of the data requires
that we discriminate between immunoprecipitations through
direct antibody contact and those through protein-dimer
interactions. To this end, extracts were boiled in 1% SDS
after cross-linking to the UV21 probe and diluted to 0.1%
SDS as described in Materials and Methods. Under these
conditions, anti-plOO immunoprecipitates only the 125-kDa
(plOO) and 65-kDa (p52) species (Fig. 4A, lane 10). Interest-
ingly, while Ab2 immunoprecipitated primarily the 60-kDa
(p50) species, a trace of the 125-kDa (plOO) species was still
brought down (Fig. 4A, lane 11). Ab22 immunoprecipitated
only the 60-kDa (p50) species (Fig. 4A, lane 12). Finally, the
anti-p65 and anti-c-Rel antisera immunoprecipitated only the
80-kDa (p65) and 88-kDa (c-Rel) species, respectively (Fig.
4A, lanes 13 and 14). We then extended these observations
by performing an identical experiment with HeLa cell nu-
clear extract. We found no detectable plOO or p52 and only
trace amounts of p5O or p65 cross-linked to the UV21 probe
(data not shown). These data are most simply explained as
showing direct physical interaction of cytoplasmic plOO and
p52 with other Rel family members.
In order to determine whether the 125-kDa complex
immunoprecipitated from boiled extract by Ab2 (Fig. 4A,
lane 11) is plOO or perhaps p105, KB-binding proteins from
the HeLa cell cytoplasmic extract were cross-linked to the
UV21 probe and incubated with an excess of Ab2932 (anti-
plOO antiserum). After removing all Ab2932-binding proteins
by incubation with PAS, the supernatant, cleared of plOO,
was incubated with Ab2. Under these conditions, we were
able to immunoprecipitate small amounts of the 60-kDa
species (p50) but not of the 125-kDa species (data not
shown). From this result, we conclude that the 125-kDa band
in Fig. 4A, lane 11, is cross-linked plOO and either that the
pSO-plOO interaction is stable enough that a small portion
reforms after boiling or that the polyclonal Ab2 is able to
recognize some minor epitopes present in plOO. The large
decrease in the presence of the 125-kDa species after boiling





























FIG. 5. Immunoprecipitation of plOO and associated proteins
from 35S-labeled HeLa cell extracts. (A) HeLa cells were labeled
with [35S]methionine and [315]cysteine as described in the text, and
labeled extracts were immunoprecipitated with anti-plOO antiserum
Ab2932 (lanes 1 and 2) or with anti-p65 antiserum AbllOl (lanes 3
and 4). Immunoprecipitations were performed in the absence (-) or
presence (+) of excess peptide against which the antibody was
made, as shown above each lane. Extract immunoprecipitated with
anti-plOO antiserum was eluted from the PAS pellet as described in
Materials and Methods and reprecipitated with anti-p65 antiserum in
the absence (-) or presence (+) of p65 peptide (lanes 5 and 6).
Immunoprecipitated proteins were analyzed by SDS-PAGE and
visualized by fluorography. Molecular size markers are shown to the
left of lane 1 (in kilodaltons). (B) HeLa cells were labeled with
[35S]methionine and [35S]cysteine and divided into cytoplasmic (CE)
and nuclear (NE) extracts as described in Materials and Methods.
Immunoprecipitations were performed from cytoplasmic extracts
(lanes 1 and 2) and from nuclear extracts (lanes 3 and 4) with
anti-plOO antiserum in the absence (lanes 1 and 3) or presence (lanes
2 and 4) of competing plOO peptide, as shown above each lane.
Immunoprecipitated proteins were analyzed by SDS-PAGE and
visualized by fluorography. Molecular size markers are shown to the
left of lane 1. Solid arrows represent plOO; open arrows represent
p65.
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Ab2 primarily through physical interaction with p5O (com-
pare lanes 3 and 11 in Fig. 4A).
We next wanted to show the physical association of plOO
with NF-KB subunits in vivo. To this end, HeLa cells were
labeled with [35S]methionine, and extracts were prepared as
described in Materials and Methods. The extracts were then
incubated with either anti-plOO or anti-p65 antiserum in the
absence and presence of blocking peptide. As shown in Fig.
SA, anti-plOO specifically immunoprecipitated a protein of
114 kDa (compare lanes 1 and 2). Interestingly, anti-p65
antiserum specifically immunoprecipitated both p65 and
plOO (Fig. 5A, compare lanes 3 and 4). The anti-plOO
antiserum has been characterized as binding preferentially to
plOO homodimers (43). Thus, it is possible that the amount of
p65 immunoprecipitated by anti-plOO antiserum is too small
to detect against the background in Fig. 5A, lane 1. In order
to lessen the background, extracts were immunoprecipitated
with anti-plOO antiserum, and specifically bound proteins
were eluted from the PAS by incubation overnight with an
excess of plOO peptide. The eluted protein was collected and
reprecipitated with anti-p65 antiserum in the absence and
presence of p65 peptide. When the background was removed
in this fashion, both plOO and p65 were immunoprecipitated
first by anti-plOO and then by anti-p65 (Fig. 5A, lane 5), and
this second immunoprecipitation was blocked by p65 peptide
1101 (lane 6). Thus, NF-KBplOO and p65 are associated in
vivo. In addition, a recent report has shown a similar rela-
tionship between plOO and other RelVNF-KcB proteins (44).
We then thought to compare cytoplasmic and nuclear
35S-labeled HeLa cell extracts for the presence of plOO.
Consistent with our previous results, plOO was seen only in
cytoplasmic extracts (Fig. SB, lane 1). No specific plOO
immunoreactivity was observed in nuclear extracts (Fig. SB,
lane 3). In addition, we attempted to detect p52 in pulse-
chase experiments. With chases of up to 7 h, cytoplasmic
plOO levels remained stable, plOO was not observed in HeLa
nuclear extracts, and at no time was p52 observed (data not
shown). Thus, plOO is quite stable in unstimulated HeLa
cells, explaining the absence of 35S-labeled p52 in our short
pulse-chase experiments.
pOO can repress p65 activation of gene expression in
transient-transfection assays. The ability of plOO to bind
NF-KB subunits and its cytoplasmic localization suggested
to us that it functions as an IKB-like molecule. We tested this
hypothesis by determining whether p65 transcriptional ac-
tivity could be repressed by plOO in transient-transfection
assays. p65 was transfected in the presence of either plOO or
the parent vector and tested for its ability to stimulate
transcription of a reporter containing three copies of the
H-2K" KB binding site fused upstream of minimal fos pro-
moter linked to the CAT gene (MHC-CAT). As shown in
Fig. 6, 200 ng of p65 expression plasmid induces a sixfold
activation of the reporter. Cotransfection of equivalent (mi-
crogram) amounts of p65 and the plOO expression plasmid
resulted in a 40 to 50% reduction in CAT activity. When the
amount of plOO DNA was increased fivefold (corresponding
to a 4.3-fold molar excess of plOO plasmid), we saw a
complete repression of p65 stimulation of the reporter. In
comparison, IKB, when transfected in equal (microgram)
amounts, can inhibit p65 to within 10% of basal expression
(9); however, it is difficult to know the relative efficiencies of
translation of the two plasmids or the stability of their
products. When the p65 DNA amount was then increased
fivefold, so that plOO and p65 expression plasmids were
again present in equal amounts, p65 activation was partially
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FIG. 6. plOO represses p65 activation in transient-transfection
assays. For each condition tested, 5 x 106 HeLa cells were
transfected by electroporation. Transfected cells were grown for 16
h and then harvested. Extracts were assayed for CAT activity and
protein concentration. (A) Each transfection mix contained 20 pg of
DNA with a constant molar amount of cytomegalovirus (CMV)
promoter DNA, 5 ,ug of the MHC3xCAT reporter, and various
amounts of CMV-p65 and CMV-plOO expression plasmids, as
shown below the graph. The data were normalized to input protein
levels and are expressed as fold activation above basal reporter
activity, representing three separate measurements from at least two
different preparations of p65 and plOO expression plasmids. (B)
Each transfection mix contained 20 ,ug of DNA with a constant
molar amount of CMV promoter DNA and 5,ug of reporter plasmid.
Each reporter plasmid was transfected in the presence or absence of
1,g of the CMV-plOO expression plasmid. The data were normal-
ized as for panel A. The basal CAT activity of each reporter alone is
assigned a value of 1. Reporter activity in the presence of 1Fg of
CMV-plOO expression plasmid is expressed as fold activation over
basal activity. Promoters are as follows: RSV, Rous sarcoma virus;
DR, MHC class II DR element; DHFR, dihydrofolate reductase
promoter; MLP, adenovirus major late promoter.
CAT expression. Thus, the effects of plOO on p65 are
titratable and depend on the ratio of p65 to plOO.
By immunoblotting, we found that cotransfected plOO had
no effect on the level of transfected p65 expression (data not
shown). Interestingly, transfected plOO protein could be
detected in the nucleus, suggesting that the ankyrin repeats
alone are not sufficient to block nuclear transport. We also
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FIG. 7. Transfected plOO sequesters p65 in the cytoplasm. COS
cells were transfected by DEAE-dextran with 10 ,ug of DNA
consisting of a constant molar amount of CMV vector DNA and
various amounts of CMV-p65 and CMV-plOO expression plasmids.
After 48 h, nuclear and cytoplasmic extracts were prepared. Lanes
1 to 3, nuclear extracts; lanes 4 to 6, matched cytoplasmic extracts.
Lanes 1 and 4, COS cells transfected with the CMV vector alone;
lanes 2 and 5, COS cells transfected with 2 pLg of CMV-p65; lanes 3
and 6, COS cells transfected with 2 pLg of CMV-p65 plus 8 Fg of
CMV-plOO. (A) Binding reactions of deoxycholate-treated extracts
with the UV21 DNA probe analyzed by EMSA. Only the shifted
bands are shown. (B) Immunoblot analysis of COS extracts
(matched to those in panel A) with the p65-specific antiserum 1101.
tested the specificity of plOO-mediated repression by replac-
ing the KB reporter with reporters unresponsive to p65,
including the adenovirus major late promoter (MLP-CAT),
the Rous sarcoma virus promoter (RSV-CAT), the MHC
class II DR promoter (DR-CAT), and the dihydrofolate
reductase promoter (DHFR-CAT). As shown in Fig. 6B,
plOO had negligible effects on the activity of these promot-
ers, suggesting that its effects are specific to p65 stimulation
rather than to basal expression. In addition, the repression of
p65 activation by plOO was observed in Jurkat and COS cells
and also in HeLa cells with a reporter driven by the HIV
long terminal repeat (data not shown).
Transfected plOO sequesters p65 in the cytoplasm. In order
to better understand the mechanism by which plOO re-
pressed p65 activation, we analyzed matched nuclear and
cytoplasmic extracts derived from transfected COS cells by
both EMSA and immunoblotting. COS cells were chosen
because our antiserum is specific for human NF-KB sub-
units, allowing us to monitor transfected cells. Deoxy-
cholate-treated nuclear and cytoplasmic extracts derived
from COS cells transfected with vector alone contain rela-
tively little NF-KB binding activity, as measured by EMSA
(Fig. 7A, lanes 1 and 4). Transfection of p65 resulted in an
increase in DNA-binding activity which was observed in
both nuclear and cytoplasmic extracts (Fig. 7A, lanes 2 and
5). When a fourfold excess of plOO expression plasmid was
cotransfected, nuclear DNA-binding activity was strongly
decreased and cytoplasmic DNA-binding activity was in-
creased and shifted to a slightly slower-migrating complex
(Fig. 7A, lanes 3 and 6). This might indicate that plOO
competes with nuclear p65 for DNA binding or that, through
heterodimerization, plOO blocks p65 from entering the nu-
cleus.
In order to discriminate between these possibilities, we
analyzed these extracts for p65 immunoreactivity by immu-
noblotting with Abll01. p65 immunoreactivity was only
observed in p65-transfected cells (Fig. 7B) and was blocked
by mixing AbllOl with the peptide from which it was
generated (data not shown). Transfection with p65 results in
the appearance of both nuclear p65 protein and a large pool
of cytoplasmic p65 (Fig. 7B, lanes 2 and 5). This cytoplasmic
pool is likely formed by the p65-mediated induction of IKBa
(14, 63). It is thought that the induction of IKBBa ensures that
physiological stimulation of NF-KB results in a transient
pulse of NF-rB activity. Cotransfection of p65 with plOO
results in the loss of nuclear p65 protein and an increase in
cytoplasmic p65 protein levels (Fig. 7B, lanes 3 and 6). Thus,
while p100 may compete with p65 for DNA binding, it
clearly sequesters p65 in the cytoplasm and, in doing so,
satisfies the functional requirements for membership in the
IKB family of NF-KB regulators.
DISCUSSION
NF-KB precursors function as IKB-like molecules. The data
presented above have shown by several experimental meth-
ods that NF-KB plOO is a DNA-binding component of H2TF1
and that NF-KB plOO is bound to NF-KB subunits in the
cytoplasm. As transfected plOO sequesters p65 in the cyto-
plasm and represses p65 activation, we interpret its cytoplas-
mic role as an IKB-like regulator of NF-KB activity. Among
the members of the rel multigene family, plOO shows the
greatest similarities with p105. This suggests that p105 might
also have plOO's IKB-like function. While this article was in
preparation, just such an observation was published by
several groups (16, 46, 53). Thus, these studies, with ours
and that of Mercurio et al. (44), together demonstrate a new
mechanism, general to NF-KB precursor molecules, by
which NF-KB activity is regulated.
The NF-KB precursor molecules plOO and p105 contain
ankyrin repeat domains homologous with those found within
the IKB family (49, 51, 56). Deletion studies have shown that
these repeat structures play a role in the inhibition of DNA
binding (27, 31, 40, 65). Interestingly, different members of
the IKB family have different affinities for NF-K-B dimers.
IKBa and pp4O bind preferentially to p65 and poorly to p5O
(9), while Bcl-3 binds specifically to p5O (65) and p52 (11).
The C-terminal region of p105, when expressed separately,
binds preferentially to p5O (40); however, p105, like plOO,
has been shown to associate with c-Rel and p65 as well (53).
This suggests that the activities of different NF-KB/Rel
complexes are regulated independently by selective activa-
tion through different IKB family members. Surprisingly,
p52/Bcl-3 complexes have recently been shown to activate
gene transcription through KB binding sites (11), indicating
that the role of ankyrin domain-containing proteins as
NF-KB regulators is complex.
The similarities between p105 and plOO caused research-
ers to look for and find an N-terminally processed form, p52,
which has been shown to synergize with p65 to activate
transcription through NF-KB sites (43, 52, 55). Therefore,
the processing of plOO-Rel family heterodimers to p52-Rel
family heterodimers allows both regulated expression of the
transcription factors and the combinatorial specificity that is
presumably associated with the control of gene expression
through various KB-like elements. An identical argument can
be made for plO5-Rel family heterodimers as well. Indeed,
others have shown by pulse-chase experiments that cyto-
plasmic plO5-Rel heterodimers give rise to nuclear p5O-Rel
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FIG. 8. Model of the regulation of NF-KB precursors. Shaded rectangles represent p65, plOO, and p52 and are identified to the left of each
rectangle. IKB is represented by a shaded oval. The Rel homology domain (rel dom.) and ankyrin repeat domain (ank. dom.) of each protein
are shown as darker shaded rectangles. The ankyrin repeat domain of plOO is shown folded over the C-terminal portion of the Rel homology
domains of p65 and plOO to indicate masking of the nuclear localization signal, in a manner similar to that of IKB. Proteolytic processing of
precursor heterodimers, IKB dissociation, and nuclear translocation of p52-p65 complexes are shown as separate steps and labeled 1 through
5. The C-terminal portion of plOO removed by proteolysis is shown in steps 1 and 4. These steps are discussed further in the text.
heterodimers upon phorbol myristate acetate stimulation
(44, 53).
Little is known of the mechanisms by which stimuli
activate NF-KB. In vitro studies have shown that phospho-
rylation of IKB blocks its ability to bind NF-KB, suggesting
that activation of a kinase is a step in the transactivation
pathway (22). Consistent with this model, we have recently
detected a phosphorylated form of IrBa following treatment
with tumor necrosis factor alpha or interleukin-1. Certain
stimuli, such as tumor necrosis factor alpha, however, have
been shown to activate NF-KB through a pathway indepen-
dent of protein kinases A and C (29, 42), which might involve
the production of oxygen radicals (57, 61). Equally little is
known of the mechanism by which proteolytic processing of
NF-KB precursors is regulated other than that it is an
ATP-dependent process (20).
The discovery that NF-KB precursors themselves seques-
ter Rel family members in the cytoplasm suggests that the
mechanisms of NF-KB activation are more complicated than
previously thought. Figure 8 summarizes our thoughts as to
how cytoplasmic precursor complexes might fit in with the
classic model of NF-KB activation. It should be noted that
this model is an extension of the data presented here and
represents a working hypothesis to be tested by future
experiments. The beginning complex is shown as a repre-
sentative plOO-p65 heterodimer; however, one could substi-
tute p105 for plOO and p5O, p52, or c-Rel for p65. In step 1,
proteolytically cleaved precursor complexes are bound by
newly synthesized IKB molecules, forming a cytoplasmic
pool of inactive NF-KB/IKB complexes. The processing of
these heterodimeric precursor complexes is probably one of
several pathways leading to a cytoplasmic pool of NF-KB/
IKB complexes. Steps 2 and 3 represent the classic NF-KB/
IKB activation pathway (see references 8, 14, and 63). Some
processed complexes might escape association with IKB and
follow step 4, resulting in a low basal level of NF-KB-like
activity. Interestingly, if the rate of proteolytic processing of
NF-KB precursor complexes is increased (due to some
physiological signal), the production of functional NF-KB-
like molecules may initially outpace the constitutive synthe-
sis of IKB, thus favoring step 4 over step 1. Under these
conditions, rapid activation of processing could constitute a
new mechanism of induction of NF-kB activity. To date, the
evidence supports a slow induction of precursor processing
(44, 53); however, future experiments may identify a stimu-
lus which mediates a more rapid induction of precursor
processing. Thus, the fate of precursor complexes appar-
ently rests on the relative rates of IKB synthesis and precur-
sor processing.
In Fig. 4, lanes 6 and 7, we detected small amounts of
cross-linked p5O and p52 immunoprecipitated from HeLa
cell cytoplasmic extracts by anti-p65 and anti-c-Rel antibod-
ies. How is it possible for cytoplasmic p5O to associate with
p65 without being bound by IKB? While the model shows the
precursors plOO and p105 binding to NF-KB subunits as
heterodimers, we cannot discount the possibility that multi-
meric complexes exist as well. Indeed, in reticuloendotheli-
osis virus T-infected cells, the multimeric v-Rel-containing
cytoplasmic complex contains p105 (16). These data can also
be explained, however, by the ability of DNA under ener-
getic UV cross-linking conditions to compete (albeit with
low affinity) with IKB for p5O binding. In this manner, UV
irradiation may trap a small portion of IcB-associated pro-
teins, covalently linking them to DNA.
Characterization of H2TF1, a cytoplasmic DNA-binding
protein complex, as containing plOO. We began this study by
analyzing the DNA-binding activity known as H2TF1. Our
data demonstrate that a major component of H2TF1 DNA-
binding activity is plOO (Lyt-10). Cross-linking experiments
(Fig. 2B and C) demonstrate that H2TF1 (the C2 complex in
gel shift assays) contains plOO as well as c-Rel, p65, p52, and
p5O; however, these are not all associated in the same
complexes (Fig. 4A). Similarly, the Cl complex contains
plOO and might contain other Rel family members. The
reason for its slower mobility in gel shift assays is unknown,
but it may represent as yet unidentified proteins associated
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with this cytoplasmic complex. The data presented here
suggest that the H2TF1 DNA-binding activity represents a
collection of plOO-Rel family member heterodimers (and
possibly multimers). Further molecular analysis of these
complexes will most likely reveal a diverse set of indepen-
dent roles rather than one concerted role for H2TF1.
Both p105 and plOO have been shown to bind poorly to
DNA in vitro (35, 47). Earlier studies characterizing these
precursor molecules as being unable to bind DNA were
performed on in vitro-translated or bacterially purified ma-
terial, whereas this study has characterized an in vivo form
of plOO. One interpretation for the ability of endogenous
H2TF1 to bind DNA effectively is that plOO is modified by a
posttranslational modification not present in plOO generated
in vitro. plOO might effectively bind DNA only when in a
heterodimeric or multimeric configuration. Alternatively, a
posttranslational modification of plOO might expose or sta-
bilize the DNA-binding domain. Another possibility is that
bacterially expressed or in vitro-translated plOO is not prop-
erly folded for efficient binding to DNA, in contrast to
H2TF1. We have recently shown that IKB sequesters NF-KB
in the cytoplasm by masking the nuclear localization signal
(9). This association functions to block the ability of NF-KB
p65 to bind to DNA. Here we show that an ankyrin repeat-
containing protein, plOO (Lyt-10), is presumably capable of
masking the nuclear localization signal without blocking the
ability of H2TF1 or the detected plOO-Rel protein het-
erodimers to bind to DNA. In this regard, the Rel domain
and the ankyrin repeat-containing domain of plOO may be
unique.
The observation that H2TF1 can bind DNA raises the
intriguing possibility that if it can enter the nucleus, it could
participate directly in the regulation of transcription through
KB sites. In this regard, the preference of some forms of
H2TF1 for the MHC class I and 2-microglobulin KB sites
(see Fig. 1) suggests that its role might involve regulation of
the expression of proteins involved in antigen presentation.
Mapping of the human p105 and plOO genes has revealed
them to be located within loci associated with translocations
in certain leukemias (41). Indeed, plOO was cloned as Lyt-10
from just such a translocation (47). The resultant chimera
retains the Rel homology domain but has lost the C-terminal
ankyrin repeats and can bind DNA as readily as in vitro-
generated plOO. As we have shown that endogenous plOO
can bind DNA, we suspect that the oncogenic potential of
the chimera is due either to the loss of cytoplasmic localiza-
tion engineered by the loss of the ankyrin repeat domain or
to an alteration in the chimera's binding specificity.
In summary, we have presented evidence for a mechanism
by which NF-KB activity is regulated through associations
with the ankyrin repeat-containing precursor protein plOO
(Lyt-10). Furthermore, these associations expand the poten-
tial for regulation through various KB sites by expanding the
combinatorial potential associated with these proteins. The
potential importance of this mechanism is illustrated by the
dysregulation of the plOO gene resulting from certain trans-
locations in B-cell lymphomas. Future experiments will be
aimed at understanding the molecular mechanisms control-
ling the processing of the NF-KB precursors and identifying
potentially new KB-like sites that respond to the relative
complexity of Rel family heterodimers. These issues are
crucial to the understanding of both NF-KB physiology and
the role of NF-KB/Rel members in the development of
cancer.
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ADDENDUM IN PROOF
An amino acid sequence derived from purified H2TF1 has
been shown to be identical to NF-KB pl00 (D. Potter, C.
Larson, P. Eckes, R. Schmid, G. Nabel, G. Verdine, and P.
Sharp, J. Biol. Chem., in press).
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